ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1317

Anti-p155/140 Autoantibodies and Selected Features at Illness Onset Are Associated with a Chronic Course of Illness in the Juvenile Idiopathic Inflammatory Myopathies

G. Esther A. Habers1, Adam M. Huber2, Gulnara Mamyrova3, Ira Targoff4, Chantal Boonacker5, Marco van Brussel1, Frederick W. Miller6, Lisa G. Rider6 and Annet van Royen-Kerkhof7, 1Child Development and Exercise Center, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands, 2IWK Health Centre, Halifax, NS, Canada, 3Rheumatology, George Washington University, Washington, DC, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands, 6Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 7Paediatric Immunology and Rheumatology, University Medical Centre Utrecht - Wilhelmina Children's Hospital, Utrecht, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: autoantibodies, juvenile dermatomyositis, juvenile myositis and prognostic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Lupus, Scleroderma and Myositis (ACR)

Session Type: Abstract Submissions (ACR)

Background/Purpose : Three types of disease courses can be distinguished in patients with juvenile idiopathic inflammatory myopathies (JIIM), namely monocyclic (M), polycyclic (P), and chronic (C). This study explored the association of demographics, clinical onset features and myositis autoantibodies with disease course in a large JIIM cohort.

Methods : In the present study, we included 365 patients with JIIM (295 dermato-, 28 poly-, and 42 overlap myositis) which were enrolled into IRB-approved studies in the US and Canada and had a disease duration > 2 years from diagnosis. Blood samples and physician questionnaires with demographics and clinical onset features were obtained. Myositis autoantibodies were determined by immunoprecipitation and blotting methods. Follow-up was performed through medical record review. The disease course classification was: M – no active disease and off medication within 2 years of diagnosis (n=88); P – disease recurrence after definite remission (n=86); and C – persistent disease or continuation of medication for > 2 years (n=191). Parameters with p<0.10 in univariate analysis were analyzed by multinomial logistic regression.

Results : Factors significant only in univariate analysis were cuticular overgrowth (M < P and C), V- and/or shawl-sign rash (M and P < C), contractures (P < C and M), photosensitivity (M < C), dyspnea at rest (P < C), palpitations and/or syncope (M and C < P), geoclimactic zone, and anti-Ro autoantibodies (M < C). Abnormal aldolase was more frequent in P compared to M and C, but not included in multivariable analysis due to missing values. Two different multinomial logistic regression analyses with non-overlapping parameters were performed (see Table 1 for results). Myositis -specific and -associated autoantibodies were more frequent in P and C than in M, with the anti-p155/140 autoantibody as the most significant (p<0.0001). Documented infections within 6 months prior to illness onset were also more frequent in the P and C compared to M. P had less early illness signs and symptoms (=lower clinical symptom score) compared to M and C. A more severe illness onset was present in C compared to M and P. Compared to M, mucous membrane involvement was less frequent in C and distal weakness was less frequent in P and C. Weight loss was more frequent in C compared to P.

Conclusion : Myositis -specific and -associated autoantibodies (especially the anti-p155/140 autoantibodies) and selected features at illness onset were associated with a chronic course of illness in patients with JIIM. These findings suggest that certain predictors of poor prognoses can be identified that might influence treatment options at illness onset.

Table 1. Results of 2 separate multinomial logistic regression analyses.

Significant parameters

p

 

OR (95% CI)

 

 

 

P vs. M

 

C vs. M

 

C vs. P

Significant parameters from analysis 1

 

 

 

 

 

 

 

   Any myositis specific autoantibodies

<0.0001

 

2.7 (1.3 to 5.7) #

 

4.0 (2.1 to 7.6) #

 

NS

   Any myositis associated autoantibodies

<0.01

 

3.8 (1.2 to 11.9) †

 

4.3 (1.6 to 12.0) #

 

NS

   Any infection 6 months prior to illness onset

<0.01

 

5.1 (2.0 to 12.7) #

 

2.4 (1.0 to 5.8) †

 

0.5 (0.2 to 1.0) †

   Clinical symptom score $

0.01

 

0.02 (0.0-0.8) †

 

NS

 

81 (4 to 1686) #

Significant parameters from analysis 2

 

 

 

 

 

 

 

   Anti-p155/140 autoantibodies

<0.0001

 

3.5 (1.2 to 10.1) †

 

7.1 (2.7 to 19.0) #

 

2.1 (0.9-4.5) *

   Severity of illness at onset

<0.01

 

NS

 

3.3 (1.5 to 7.3) #

 

2.2 (1.0 to 4.9) *

   Mucous membrane involvement

0.02

 

NS

 

0.3 (0.1 to 0.7) #

 

NS

   Distal weakness

0.04

 

0.4 (0.2 to 0.8) †

 

 0.5 (0.2 to 1.0) *

 

NS

   Weight loss

0.03

 

NS

 

NS

 

3.1 (1.3 to 7.6) †

Data was adjusted for date of diagnosis and for the significant parameters in the analysis.

*p≤0.10

†p≤0.05

#p≤0.01

$ Odds ratio: per 0.01 increase in clinical symptom score


Disclosure:

G. E. A. Habers,
None;

A. M. Huber,
None;

G. Mamyrova,

Cure JM Foundation,

2;

I. Targoff,
None;

C. Boonacker,
None;

M. van Brussel,
None;

F. W. Miller,
None;

L. G. Rider,
None;

A. van Royen-Kerkhof,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-p155140-autoantibodies-and-selected-features-at-illness-onset-are-associated-with-a-chronic-course-of-illness-in-the-juvenile-idiopathic-inflammatory-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology